Jiuzhou Pharmaceutical

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. was founded in 1973, with over 4,300 employees. In 2021, its operating revenue was 4 billion yuan. It was listed on the Shanghai Stock Exchange on October 10, 2014 (stock abbreviation: Jiuzhou Pharmaceutical; stock code: 603456). The company is a high-tech pharmaceutical enterprise, mainly engaged in custom new drug development and production services (CDMO), and specialty active pharmaceutical ingredients and intermediates (API). The company has branches in Taizhou, Zhejiang; Hangzhou, Zhejiang; Yancheng, Jiangsu; Suzhou, Jiangsu; Hong Kong, as well as in countries such as the United States and Denmark. The company mainly produces drugs in therapeutic areas such as central nervous system, anti-infective, non-steroidal anti-inflammatory, anti-diabetic, and cardiovascular. It is a global major manufacturer and supplier of carbamazepine API and intermediates, and ketoprofen API and intermediates. The company has successively received honors such as Top 100 Pharmaceutical Enterprises in China, National Leading Enterprise in API Export, and National Technology Innovation Demonstration Enterprise.
Adhering to the corporate mission of "Caring for life, maintaining health," the company always upholds the corporate philosophy of "Promoting quality leaps through unremitting efforts." It has successively established ISO9001 Quality Management System, ISO14001 Environmental Management System, and OHSAS18001 Occupational Health and Safety Management System, and has passed national GMP, US FDA, European COS and other official certifications. It has established strategic cooperative relationships with multiple well-known multinational pharmaceutical companies. Over 80% of the company's products are exported to Europe, the Americas, Southeast Asia and other countries and regions, gaining worldwide reputation.
The company is committed to research and investment in new pharmaceutical technologies, and has established a nationally recognized enterprise technology center and a national postdoctoral research workstation. There are currently over 800 R&D personnel. The company has participated in national 863 program projects, major national scientific and technological achievement transformation projects, and multiple other provincial and ministerial major projects and has won awards. Among them, the "Research and Application of Key Technology for Fixed-bed Catalytic Dehydrogenation to Produce Iminostilbene (ISB)" project won the second prize of the National Science and Technology Progress Award.
Thinking about the future with the future, creating the future with the present. Today, Jiuzhou Pharmaceutical once again stands at a new starting point of development. Adhering to the core values of "Customer first, strict innovation, honesty and trustworthiness, unity and progress," the company will surely dedicate itself to the development of the national pharmaceutical industry with "excellent products, superb technology, and meticulous service," and make greater contributions to human health.